InvestorsHub Logo
Followers 47
Posts 3929
Boards Moderated 0
Alias Born 03/04/2012

Re: frenchbroad post# 374332

Wednesday, 09/15/2021 11:09:28 AM

Wednesday, September 15, 2021 11:09:28 AM

Post# of 403481
Important quote from one of the discoverers of Brilacidin, thanks for the reminder:

“It is a rewarding moment for me, as one of the discoverers of Brilacidin, to see Brilacidin continue to receive validation as a promising antiviral treatment—based both on in silico molecular modeling studies and lab research,” commented William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), and Scientific Advisor for Innovation Pharma. “COVID-19 is, in all likelihood, here to stay. Bringing to market effective coronavirus therapeutics with novel mechanisms less prone to drug resistance developing due to mutations, a characteristic Brilacidin is exhibiting, will be important as the world combats this infectious and deadly virus. I look forward to seeing how Brilacidin performs in its Phase 2 trial in hospitalized COVID-19 patients and am hopeful Brilacidin will emerge as an effective antiviral, with added beneficial immunomodulatory properties.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News